Navigation Links
Prominent Advocate on HIV/AIDS Issues Joins Altarum Institute
Date:4/25/2008

Jesse Milan Joins Nonprofit Health Systems Research Institute as New Vice

President

WASHINGTON, April 25 /PRNewswire/ -- Jesse Milan, Jr., prominent leader and advocate on HIV/AIDS issues, has joined the nonprofit Altarum Institute as Vice President and Director of its Community Health Systems Group.

"When we began the search for someone to lead our Community Health Systems Group, I hoped to find an individual with expertise in health issues, a network of contacts in the health community, and experience leading research and consulting efforts," said Lincoln Smith, President and CEO of Altarum. "With Jesse, we've found all three."

A person living with HIV for 26 years, Milan has spoken and written extensively on HIV/AIDS issues. From 2002-2007, he served as co-chair of the Centers for Disease Control and Prevention (CDC)/Health Resources and Services Administration (HRSA) Advisory Committee on HIV and STD Prevention and Treatments. He recently co-authored an article on a national HIV prevention plan.

Milan received the "Hero in the Struggle" award in 2008 from the Black AIDS Institute. He was honored by HRSA in 2004 for "leading the national and international fight against HIV disease." Milan is past director of the City of Philadelphia AIDS Office, and served as president of the boards of Action AIDS; the Philadelphia AIDS Consortium; and the National Episcopal AIDS Coalition. He is currently board chair of the Black AIDS Institute.

Prior to joining Altarum, Milan was Senior Principal for Health Policy and Promotion at SRA Constella Group, where he also served as Vice President for Global Health Convergence and Vice President for Health Communications. Milan served for six years as Constella's Project Director for the CDC's National Prevention Information Network, the world's largest service for information on HIV/AIDS, STDs, and tuberculosis.

Milan is former Chief of Staff to the Presi
'/>"/>

SOURCE Altarum Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Two Prominent Nebraska Doctors Become Patients in Living Donor Liver Transplant
2. Highmark, Prominent Part of Pittsburgh City Skyline, to Go Dark for One Hour to Support the Environment
3. Prominent Cosmetic Dermatologist and Author Joins MySkinCareConnection.com
4. Prominent Health Care Executive, Kevin Kraushaar, Joins Triadvocates LLC as Managing Principal of DC Office
5. Prominent Respiratory Therapist and Author Joins StopSmokingConnection.com as a COPD Expert
6. Prominent Orthopaedic Hand and Upper Extremity Surgeon Joins Radlink Board of Directors
7. Prominent Chick Lit Novelist Laura Zigman Joins HealthCentrals MyBreastCancerNetwork.com as Expert
8. Prominent Farmington Plastic Surgeon Uses Two New Non-Surgical Procedures to Tighten Skin and Remove Fat
9. Prominent Cosmetic Dentist Dr. William Hoskyns Joins Leading Atlanta Practice
10. Teenage suicides: Study advocates greater family support
11. Nations Premiere Patient Advocate Organization Commits to UCN inContact(R) for Entire Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...has been little research about the physical activi...ts are exercising and what // they are doing could...ograms for asthma patients. Doctors from the Cente...nducted a study to look at the physical activity l...
...suffering from back pain, pelvic pressure, frequen...could be to blame. Fibroids are non-cancerous // g...rom very small to the size of a cantaloupe or larg...ne fibroid embolization -- a treatment that’s beco...
...tis is a common health problem worldwide. Both ost...ain and stiffness in patients.There is no cure for...maged cartilage. // A new study could help lead do...t of arthritis. The research pinpoints the molecul...
...study finds angioplasty should be the treatment of...pital they initially go to doesn’t offer angioplas...nother facility for treatment. Research has shown ...hey are treated with angioplasty to open up the cl...
Other Medicine News:
(Date:8/27/2008)...tients in the VELCADE, melphalan and prednisone ar... well as a 30 percent complete response -, CAMBRI...e Takeda,Oncology Company today announced the publ...d, Phase III VISTA(1) trial in this week,s edition...ts showed a significant survival,benefit and a 30 ...
(Date:8/27/2008)...First Phase 3 data, from BLISS-52 trial, expected ...LISS-76, expected by fall 2009 -, ROCKVILLE, Md.,...iences, Inc. (Nasdaq: HGSI ) today announced it h...S-76, the second of two pivotal Phase 3,randomized... patients with,active systemic lupus erythematosus...
(Date:8/26/2008)...IANAPOLIS, Aug. 26 /- Semafore Pharma...national Congress on Targeted Therapies,in Cancer ...ovel,multi-targeted kinase inhibitors that demonst...l studies., A novel and proprietary molecular sca...ing allowing for the design of pan-PI3 kinase inhi...
(Date:8/26/2008)...LO PARK, Calif., Aug. 26 /-... the positive one-year follow-up data,from the CUS...e of the,peer-reviewed journal, EuroIntervention. ...tella, M.D., of University Medical Center Utrecht,...II Investigators from 13 clinical,sites across Eur...
Breaking Medicine Technology:New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4Blood pressure drug telmisartan shows powerful activity against stroke 1570 1Blood pressure drug telmisartan shows powerful activity against stroke 1570 2Blood pressure drug telmisartan shows powerful activity against stroke 1570 3Ireland Cancer Center researchers advance stem cell gene therapy 1565 1Ireland Cancer Center researchers advance stem cell gene therapy 1565 2Ireland Cancer Center researchers advance stem cell gene therapy 1565 3Wind power explored off Californias coast 1563 1Wind power explored off Californias coast 1563 2Wind power explored off Californias coast 1563 3Wind power explored off Californias coast 1563 4Ceregene Presents Long term Follow up From Phase 1 Trial of CERE 120 in Parkinsons Disease 1050 1Ceregene Presents Long term Follow up From Phase 1 Trial of CERE 120 in Parkinsons Disease 1050 2Ceregene Presents Long term Follow up From Phase 1 Trial of CERE 120 in Parkinsons Disease 1050 3Ceregene Presents Long term Follow up From Phase 1 Trial of CERE 120 in Parkinsons Disease 1050 4
... 20, 2007 /PRNewswire-FirstCall/ --,Alfacell Corpo... to,act as a potent payload in antibody conjugates...on of the Handbook of Therapeutic,Antibodies. , In...Susanna,Rybak, Ph.D. summarizes preclinical resear...ONCONASE improves in a number of tumor,models, inc...
...nzyme Levels in Two Most Common Mutations, CRANBUR...rapeutics, a biopharmaceutical company developing ...l chaperones for the,treatment of a range of human...esent the results of preclinical studies of,Plicer...isease at,the of Medical Genetics (ACMG) annual me...
Other Medicine Technology:Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 2Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 3Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 4Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 2Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 3
A full, rounded look that adds greater dimension to the breast. Moderate base, with a higher profile than our Style 1600 implant.
The Advanta™ PTFE facial implant is an expanded porous polytetrafluoroethylene,material that is intended for augmentation or repair of the soft tissues of the facial,area. This product is avail
Chin Implants are used for cosmetic augmentation, repairing trauma related injuries and genetic deficiencies. They are inserted through an incision in the mouth below the incisor teeth or through an
The IEC CL40 and FL40 Centrifuge Series from Thermo Electron combines power, safety and versatility to increase your productivity in the lab. Available with a broad array of rotors and accessories fo
Medicine Products: